select a format

Single User License
USD 250 INR 16258
Site License
USD 500 INR 32515
Corporate User License
USD 750 INR 48773

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Merck & Co Inc (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Merck & Co Inc (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH6319D
  • |
  • Pages: 400
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Merck & Co Inc (Merck) focuses on the discovery, development, manufacture and commercialization of prescription pharmaceuticals, biologic therapies, vaccines and animal healthcare products. It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respiratory and women's diseases, diabetes and vaccines. The company provides animal health products including vaccines, poultry products, livestock products and aquaculture products. Merck sells pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company's operations outside the US are conducted primarily through subsidiaries. It offers its products in US, Europe, Middle East and Africa, Asia Pacific, Japan, Latin America and other countries. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Merck & Co Inc (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 10

List of Figures 16

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 17

Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 18

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 19

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 20

Merck & Co Inc, Medical Devices Deals, 2011 to YTD 2017 22

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 23

Merck & Co Inc, Pharmaceuticals & Healthcare, Deal Details 39

Asset Purchase 39

Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 39

Adolor Reacquires Rights Of ENTEREG From GlaxoSmithKline 40

Venture Financing 41

Grail Raises Funds in First Tranche of Series B Financing 41

Just Biotherapeutics Raises USD14 Million in Series A2 Financing 43

Just Biotherapeutics Raises USD15 Million in Series A Financing Round 44

RaNA Therapeutics Raises USD55 Million in series B Financing 45

Gladius Pharma Raises USD3.3 Million in Series A Financing 46

NGM Biopharma Raises USD106 Million in Series E Financing 47

EnGene Raises USD11 Million in Series B Venture Financing 48

OsteoQC Raises Funds in Venture Financing 48

AdvanDx Raises US$12 Million In Series B-1 Venture Financing 49

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 50

OncoEthix Raises US$19 Million In Series B Financing 51

Aviir Raises US$20 Million In Venture Financing 52

cCAM Biotherapeutics Raises US$6 Million In Series A Financing 53

Aviir Secures US$10 Million In Venture Financing 54

High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 55

BeiGene Receives Investment From Merck Sharp & Dohme 56

Partnerships 57

CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 57

OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 58

Array BioPharma Enters into Agreement with Merck 58

Atara Biotherapeutics Enters into Agreement with Merck 59

HitGen Enters into Agreement with Merck 60

BerGenBio Enters into Agreement with Merck 61

Stratophase Enters into Agreement with Merck 62

CMIC Enters into Agreement with MSD for Diazoxide 62

Ramot at Tel Aviv University Enters into Research Agreement with Merck 63

NOXXON Pharma Enters into Agreement with Merck 64

Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 65

Proteros biostructures Enters into Agreement with Merck Sharp & Dohme 66

Genexine Enters into Clinical Research Agreement with Merck 66

Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 67

Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 68

Merck Enters into Distribution Agreement with JenKem Tech 69

MSD Enters into Agreement with Kyorin Pharma 69

Agency for Science, Technology and Research Enters into Agreement with Merck 70

Menarini Asia-Pacific Enters into Agreement with Merck 71

Innovative Targeting Solutions Enters into Research Agreement with Merck 72

Fujifilm Diosynth Biotech Partners with Merck 73

Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 73

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 74

Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 75

ImmunoGen Enters into Research Agreement with Merck 76

Merck Enters into Agreement with AbCellera Biologics 77

Affimed Enters into Research Agreement with Merck 77

BioLineRx Enters into Agreement with Merck 78

Quartet Medicine Enters into Agreement with Merck 79

Complix Enters into Agreement with Merck 80

Eli Lilly Expands its Agreement with Merck 81

Merck Enters into Agreement with Akeso Biopharma 82

Amgen and Merck Enter into Agreement 82

Viralytics Enters into Agreement with Merck 83

GlaxoSmithKline Partners with Merck 84

Synthace Enters into Agreement with Merck 85

MacroGenics Enters into Agreement with Merck 85

Incyte Extends Partnership with Merck 86

Merck Enters into Agreement with OBI Pharma 87

Merck Enters into Agreement with DNAtrix 88

Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 89

Immune Design Enters into Clinical Collaboration Agreement with Merck 89

Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 90

Merck Sharp & Dohme Expands its Agreement with NanoString Technologies 91

Plexxikon Enters into Agreement with Merck 92

PeptiDream Enters into Peptide Discovery Agreement with Merck 93

Organovo Enters into Research Agreement with Merck Sharp & Dohme 93

Astellas Pharma to Enter into Agreement with MSD 94

Syndax Pharma Expands its Agreement with Merck 95

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 96

NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 97

Merck Expands Agreement with Eli Lilly 98

Enumeral Biomedical Amends its Agreement with Merck Sharp & Dohme 99

Kyorin Pharma Amends Co-Marketing Agreement with MSD 99

Bind Therapeutics Enters into R&D Agreement with Merck 100

Advaxis Enters into Agreement with Merck 101

Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 102

Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 103

Merck Enters Into Co-Development Agreement With Samsung Bioepis For MK-1293 104

Dako Enters Into Co-Development Agreement With Merck 105

Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 106

Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 107

Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 108

Abide Therapeutics Enters Into Co-Development Agreement With Merck 109

Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 110

Merck And Samsung Bioepis Enter Biosimilars Development Agreement 111

Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 112

Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 113

Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 114

ActoGeniX Enters Into Research Agreement With Merck 115

TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 115

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 116

ALK Enters Into Co-Promotion Agreement With MSD For Grazax 117

Redbiotec Extends Drug Discovery Agreement With Merck 118

Merck Forms Joint Venture With Supera Farma Laboratorios 119

MSD Enters Into Distribution Agreement With Julphar 120

AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 121

Fundacion Medina Enters Into Research Agreement With Cubist Pharma 122

Chongqing Zhifei Biological Products Extends Co-Marketing Agreement With Merck For RotaTeq 123

Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 124

Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 125

MSD India Plans Co-Marketing Agreement For Diabetes Drugs 126

Ezose Sciences Enters Into Co-Development Agreement With Merck 127

Vaccine & Gene Therapy Institute Enters Research Agreement With Merck 127

Redbiotec Enters Into Drug Discovery Agreement With Merck 128

Merck Enters Into Co-Development Agreement With Beijing Genomics Institute 128

Merck Enters Into Co-Development Agreement With Serum Institute of India 129

Merck Extends Co-Promotion Agreement With Roche For VICTRELIS 130

Merck Enters Into Co-Promotion Agreement With Daewoong Pharma For Vytorin 131

MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat 132

MSD In India Enters Into Co-Marketing Agreement With Sun Pharma 133

Merck Amends Distribution Agreement With Johnson & Johnson 134

Optimer Pharma Enters Into Co-Promotion Agreement With Cubist Pharma 136

TPP Global Development Enters Into Agreement With University of Aberdeen 137

ARIAD Announces Co-Promotion Agreement With Merck 138

Lycera Enters Into Research Agreement With Merck 139

Merck Enters Into An Agreement With PAREXEL International 140

Licensing Agreements 141

Kyorin Pharma Enters into Licensing Agreement with Merck 141

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 142

Merck Enters into Licensing Agreement with BioNovion 143

Zymeworks Extends Licensing Agreement with Merck 144

Zymeworks Enters into Licensing Agreement with Merck 145

Merck Enters into Licensing Agreement with Moderna Therapeutics 146

Merck Enters into Licensing Agreement with Harvard University 147

Merck Enters into Licensing Agreement with AureoGen Biosciences 148

Merck Enters into Licensing Agreement with Cancer Research Technology 148

Adimab Enters into Licensing Agreement with Merck 150

Merck Enters into Licensing Agreement with Selvita 150

Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 151

Allergan Enters into Licensing Agreement with Merck 153

Merck Extends Licensing Agreement with Agenus 154

Arvinas Enters into Licensing Agreement with Merck 155

Merck Enters into Licensing Agreement with Medicines Patent Pool 156

XL-protein Enters into Licensing Agreement with MSD Animal Health 157

Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 158

EnWave Enters into Licensing Agreement with Merck 159

Merck Enters into Licensing Agreement with NewLink Genetics 160

Euroscreen Enters into Licensing Agreement with Merck 161

Sun Pharma Enters into Licensing Agreement with Merck 162

Kyorin Pharma Enters into Licensing Agreement with Merck 163

Bionomics Enters into Licensing Agreement with Merck for BNC375 164

Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 165

Gulf Pharma Enters into Licensing Agreement with MSD 166

NanoBio Enters Into Licensing Agreement With Merck 167

Nuevolution Enters Into Licensing Agreement With Merck 167

Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 168

Merck Expands Licensing Agreement with Ablynx 170

Polyplus-transfection Enters Into Licensing Agreement With Merck 171

AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 172

Depomed Expands Licensing Agreement With Merck For Metformin Patents 173

Bionomics Extends Licensing Agreement with Merck 174

Merck Enters Into Licensing Agreement With Lupin 175

Xencor Enters Into Licensing Agreement With Merck 176

Cerecor Enters Into Licensing Agreement With Merck For MK-0657 177

Merck Exercises Option For Licensing Agreement With Xenon Pharma For Cardiovascular Disease Targeted Compounds 178

Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 179

Merck Enters into Licensing Agreement with Ra Pharma 180

Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 181

Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 182

Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 183

Menlo Therapeutics Enters into Licensing Agreement with Merck 184

Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 185

Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 186

Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 186

Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 187

Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 189

MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 190

Merck Enters Into Licensing Agreement With Yamasa For EFdA 190

Merck Enters Into Licensing Agreement With Chimerix For CMX157 191

R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 192

Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 193

OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 194

Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 195

Merck Enters Into Licensing Agreement With Numerate For In Silico Drug Design Technology 196

Merck Extends Licensing Agreement with Codexis 197

Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 198

Exelixis Enters Into Licensing Agreement With Merck For PI3K-delta 199

Mochida Pharma Enters Into Licensing Agreement With Merck 200

Bend Research Enters Into Licensing Agreement With Merck 201

Hawaii Biotech Enters Into Licensing Agreement With Merck 202

Merck Enters Into Licensing Agreement With FKD Therapies 202

AbD Serotec Amends Licensing Agreement With Merck 203

Trius Therapeutics Enters Into Licensing Agreement With Bayer HealthCare For Torezolid Phosphate 204

MSD Enters Into Licensing Agreement With Astellas US For vernakalant 205

Hanwha Chemical Enters Into Licensing Agreement With Merck For HD203 206

Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 207

Equity Offering 208

Bionomics Raises USD9 Million in Private Placement of Shares 208

OpGen Raises USD5 Million in Private Placement of Shares 209

BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 210

Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 211

BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 212

Trius Therapeutics Completes Public Offering Of Shares For US$34 Million 213

Trius Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$5 Million 214

VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 215

Trius Therapeutics Completes Over-allotment Option Of Underwritten Public Offering For US$52 Million 216

Trius Therapeutics Completes Private Placement Of Units For US$30 Million 218

Debt Offering 219

Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 219

Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 220

Merck Completes Public Offering of Notes Due 2020 for USD1.25 Billion 221

Merck Completes Public Offering of Notes Due 2022 for USD1.25 Billion 223

Merck Completes Public Offering of Notes Due 2020 for USD700 Million 224

Merck Completes Public Offering of Notes Due 2025 for USD2.5 Billion 226

Merck Completes Public Offering of Notes Due 2017 for USD300 Million 228

Merck Completes Public Offering of Notes Due 2045 for USD2 Billion 229

Merck Raises USD1.25 Billion in Public Offering of 1.875% Notes Due 2026 231

Merck Raises USD625 Million in Public Offering of 2.5% Notes Due 2034 232

Merck Raises USD1.25 Billion in Public Offering of 1.125% Notes Due 2021 234

Cubist Pharma Completes Private Placement Of Notes Due 2020 For US$450 Million 236

Cubist Pharma Completes Private Placement Of Notes Due 2018 For US$350 Million 237

Merck Completes Public Offering Of Notes Due 2016 For US$500 Million 237

Merck Completes Public Offering Of Notes Due 2016 For US$1 Billion 239

Merck Completes Public Offering Of Notes Due 2018 For US$1 Billion 241

Merck Completes Public Offering Of Notes Due 2023 For US$1.75 Billion 242

Merck Completes Public Offering Of Notes Due 2043 For US$1.25 Billion 244

Merck Completes Public Offering Of Floating Notes Due 2018 For US$1 Billion 246

BeiGene Raises USD3 Million in Private Placement of Notes 248

Merck Completes Public Offering Of Notes Due 2042 For US$500 Million 248

Merck Completes Public Offering Of 1.1% Notes Due 2018 For US$1 Billion 250

Merck Completes Public Offering Of Notes Due 2022 For US$1 Billion 251

Asset Transactions 252

Pharmaron Acquires Hoddesdon UK Site from Merck Sharpe & Dohme 252

Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 253

ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 254

Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 255

Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 256

Merial to Acquire Manufacturing Facility from Merck 257

Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck for USD50 Million 258

Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 260

AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 262

KBI Biopharma To Acquire Biologics Operations Of Merck 264

Amphastar Pharmaceuticals Acquires API manufacturing business of Merck 264

Oak Pharma Acquires Tafluprost Business from Merck 265

Aspen Acquires Portfolio of Drugs from Merck for USD600 Million 266

Forest Labs To Acquire US Marketing Rights To Saphris From Merck Sharp & Dohme For US$240 Million 269

CCS Healthcare To Acquire Propyless From Merck Sharp & Dohme 270

Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 271

Cerecor Acquires Rights To COMT Inhibitors From Merck 272

Kyorin Acquires Production Facility from MSD 273

Acquisition 274

Merck Acquires Afferent Pharma 274

Merck Acquires IOmet Pharma 275

Merck Acquires cCAM Biotherapeutics 275

Merck Acquires Cubist Pharma for USD9.5 Billion 276

Merck Acquires OncoEthix for USD375 Million 279

Merck Completes Acquisition of Idenix Pharma for USD3.85 Billion in Tender Offer 279

Alnylam Pharma Completes Acquisition Of Sirna Therapeutics From Merck 281

Akorn Acquires Inspire Pharma From Merck For US$53 Million 282

Cubist Pharma Completes Acquisition Of Optimer Pharma For Up To US$801 Million 284

Cubist Pharma Completes Acquisition Of Trius Therapeutics For Up To US$818 Million In A Tender Offer 285

Telerx Acquires Sentrx Safety Solutions, Pharmacovigilance Outsourcing Company 287

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 288

Merck Plans To Acquire Micro Labs, Maker Of Generic Drugs 290

Cubist Pharma Completes Acquisition Of Adolor For US$415 Million 290

Johnson & Johnson Acquires Johnson & Johnson Merck Consumer Pharma From Merck Sharp & Dohme For US$175 Million 292

Nuvisan Acquires Essex Pharma Development From Merck 292

Merck Completes Acquisition Of Inspire Pharma 293

Fujifilm Completes Acquisition Of MSD Biologics 296

Fujifilm Completes Acquisition Of Diosynth 297

Merck & Co Inc - Key Competitors 299

Key Employees 300

Locations And Subsidiaries 302

Head Office 302

Other Locations & Subsidiaries 302

Recent Developments 329

Strategy And Business Planning 329

Mar 02, 2017: Allergopharma Opens new Biopharmaceutical Production in Reinbek 329

Jan 13, 2016: BioMed X Merck collaboration in the field of selective kinase inhibitors reaches major milestone 330

Financial Announcements 331

May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 331

Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 333

Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 335

May 05, 2016: Merck Announces First-Quarter 2016 Financial Results 338

Feb 03, 2016: Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results 340

Corporate Communications 343

Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 343

May 23, 2016: Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million Initiative to Improve Access to High-Quality Cancer Care in Underserved Communities in the United States 344

Mar 07, 2016: Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire 345

Mar 04, 2016: Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa 346

Legal and Regulatory 347

Feb 15, 2017: Mercks Wholly Owned Subsidiary Idenix Pharmaceuticals Awarded $2.54 Billion for Infringement of a Hepatitis C Drug Patent 347

Dec 16, 2016: Merck's subsidiary wins $2.5bn patent verdict against Gilead Sciences 348

Mar 22, 2016: Ionis Pharmaceuticals and Merck Receive Positive Verdict on Gilead HCV Drug Patent Case 349

Jan 15, 2016: Merck Sues Merck for Improper Use of Merck 350

Government and Public Interest 351

Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 351

Feb 09, 2017: Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care 352

Jan 19, 2017: MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers 353

Jan 18, 2017: Merck Foundation Grant Expands Project ECHO in Vietnam and India 354

Sep 29, 2016: Merck Foundation Grant Expands YMCAs Diabetes Prevention Program in Five States 355

Jun 06, 2016: GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com 356

Mar 24, 2016: Merck Foundation Awards Grant to American Cancer Society for Program to Improve Access to High-Quality Cancer Care in Underserved Communities 358

Product News 359

12/28/2016: AHF lauds the research community on an experimental Ebola vaccine that showed 100% efficacy in a clinical trial 359

12/22/2016: Final Trial Results Confirm Ebola Vaccine Provides High Protection Against Disease 360

10/26/2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016 362

Sep 27, 2016: IDH and CIC Mutations Provide Prognostic Information for Grade II and III Gliomas 363

09/05/2016: Hypertension: releasing the pressure at its source 364

Jul 18, 2016: Publication of HPTN 052 final results 366

06/16/2016: Cempra to Host Analyst and Investor Day on June 23, 2016 367

06/10/2016: Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference 368

04/19/2017: Merck to Present Data on Relebactam at ECCMID 2017 369

04/07/2016: Merck To Present Data on ZERBAXA at ECCMID 2016 370

02/22/2016: New Antibiotic Against Drug-Resistant Bacteria Now Available 371

02/05/2016: The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra Oral Solithromycin in Community-Acquired Bacterial Pneumonia 372

Product Approvals 373

Jul 25, 2016: Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920) 373

Jul 05, 2016: Cempra Announces FDA Acceptance of Solithera New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia 374

Jun 28, 2016: Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 375

May 01, 2016: Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 376

Mar 18, 2016: ONO Receives Approval for PROEMEND for Intravenous Infusion 150 mg for Treatment of Chemotherapy-Induced Nausea and Vomiting for a Partial Change in Approved Items for Additional Application to Pediatric Patients 377

Feb 04, 2016: FDA Approves Mercks Single-Dose EMEND (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy 378

Clinical Trials 379

Dec 05, 2016: Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD 379

Oct 18, 2016: Canadian Ebola vaccine enters new trial phase 380

Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe 381

Jun 15, 2016: Merck Highlights Data on relebactam in combination with imipenem/cilastatin at ASM Microbe 2016 382

Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016 383

May 25, 2016: Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation) 384

May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference 385

May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 387

May 12, 2016: Cempra to Present Solithromycin IV Data at ATS 2016 389

May 02, 2016: Ebola vaccine: Promising phase I trials 390

Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference 391

Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference 392

Apr 04, 2016: Cempra to Present Data on Solithromycin at ECCMID 393

Feb 01, 2016: Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin 394

Jan 05, 2016: Cempra Doses Initial Patient in Phase 2 Clinical Trial of Solithromycin in NASH 395

Other Significant Developments 396

Feb 16, 2017: Mercks Fight Against Infectious Disease Goes Digital with Launch of ILUM Health Solutions 396

Oct 14, 2016: Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community 397

Jun 09, 2016: Menarini Group and MSD Extends Global Partnership to the Asia-Pacific Region 398

Jun 08, 2016: Merck Expands its Investment Fund Merck Ventures 399

Appendix 400

Methodology 400

About GlobalData 400

Contact Us 400

Disclaimer 400

List of Figures

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 17

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 18

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 19

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 20

Merck & Co Inc, Medical Devices Deals, 2011 to YTD 2017 22

List of Tables

Merck & Co Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 17

Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 18

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 19

Merck & Co Inc, Deals By Therapy Area, 2011 to YTD 2017 20

Merck & Co Inc, Medical Devices Deals, 2011 to YTD 2017 22

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 23

Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 39

Adolor Reacquires Rights Of ENTEREG From GlaxoSmithKline 40

Grail Raises Funds in First Tranche of Series B Financing 41

Just Biotherapeutics Raises USD14 Million in Series A2 Financing 43

Just Biotherapeutics Raises USD15 Million in Series A Financing Round 44

RaNA Therapeutics Raises USD55 Million in series B Financing 45

Gladius Pharma Raises USD3.3 Million in Series A Financing 46

NGM Biopharma Raises USD106 Million in Series E Financing 47

EnGene Raises USD11 Million in Series B Venture Financing 48

OsteoQC Raises Funds in Venture Financing 48

AdvanDx Raises US$12 Million In Series B-1 Venture Financing 49

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 50

OncoEthix Raises US$19 Million In Series B Financing 51

Aviir Raises US$20 Million In Venture Financing 52

cCAM Biotherapeutics Raises US$6 Million In Series A Financing 53

Aviir Secures US$10 Million In Venture Financing 54

High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 55

BeiGene Receives Investment From Merck Sharp & Dohme 56

CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 57

OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 58

Array BioPharma Enters into Agreement with Merck 58

Atara Biotherapeutics Enters into Agreement with Merck 59

HitGen Enters into Agreement with Merck 60

BerGenBio Enters into Agreement with Merck 61

Stratophase Enters into Agreement with Merck 62

CMIC Enters into Agreement with MSD for Diazoxide 62

Ramot at Tel Aviv University Enters into Research Agreement with Merck 63

NOXXON Pharma Enters into Agreement with Merck 64

Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 65

Proteros biostructures Enters into Agreement with Merck Sharp & Dohme 66

Genexine Enters into Clinical Research Agreement with Merck 66

Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 67

Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 68

Merck Enters into Distribution Agreement with JenKem Tech 69

MSD Enters into Agreement with Kyorin Pharma 69

Agency for Science, Technology and Research Enters into Agreement with Merck 70

Menarini Asia-Pacific Enters into Agreement with Merck 71

Innovative Targeting Solutions Enters into Research Agreement with Merck 72

Fujifilm Diosynth Biotech Partners with Merck 73

Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 73

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 74

Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 75

ImmunoGen Enters into Research Agreement with Merck 76

Merck Enters into Agreement with AbCellera Biologics 77

Affimed Enters into Research Agreement with Merck 77

BioLineRx Enters into Agreement with Merck 78

Quartet Medicine Enters into Agreement with Merck 79

Complix Enters into Agreement with Merck 80

Eli Lilly Expands its Agreement with Merck 81

Merck Enters into Agreement with Akeso Biopharma 82

Amgen and Merck Enter into Agreement 82

Viralytics Enters into Agreement with Merck 83

GlaxoSmithKline Partners with Merck 84

Synthace Enters into Agreement with Merck 85

MacroGenics Enters into Agreement with Merck 85

Incyte Extends Partnership with Merck 86

Merck Enters into Agreement with OBI Pharma 87

Merck Enters into Agreement with DNAtrix 88

Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 89

Immune Design Enters into Clinical Collaboration Agreement with Merck 89

Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 90

Merck Sharp & Dohme Expands its Agreement with NanoString Technologies 91

Plexxikon Enters into Agreement with Merck 92

PeptiDream Enters into Peptide Discovery Agreement with Merck 93

Organovo Enters into Research Agreement with Merck Sharp & Dohme 93

Astellas Pharma to Enter into Agreement with MSD 94

Syndax Pharma Expands its Agreement with Merck 95

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 96

NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 97

Merck Expands Agreement with Eli Lilly 98

Enumeral Biomedical Amends its Agreement with Merck Sharp & Dohme 99

Kyorin Pharma Amends Co-Marketing Agreement with MSD 99

Bind Therapeutics Enters into R&D Agreement with Merck 100

Advaxis Enters into Agreement with Merck 101

Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 102

Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 103

Merck Enters Into Co-Development Agreement With Samsung Bioepis For MK-1293 104

Dako Enters Into Co-Development Agreement With Merck 105

Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 106

Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 107

Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 108

Abide Therapeutics Enters Into Co-Development Agreement With Merck 109

Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 110

Merck And Samsung Bioepis Enter Biosimilars Development Agreement 111

Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 112

Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 113

Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 114

ActoGeniX Enters Into Research Agreement With Merck 115

TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 115

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 116

ALK Enters Into Co-Promotion Agreement With MSD For Grazax 117

Redbiotec Extends Drug Discovery Agreement With Merck 118

Merck Forms Joint Venture With Supera Farma Laboratorios 119

MSD Enters Into Distribution Agreement With Julphar 120

AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 121

Fundacion Medina Enters Into Research Agreement With Cubist Pharma 122

Chongqing Zhifei Biological Products Extends Co-Marketing Agreement With Merck For RotaTeq 123

Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 124

Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 125

MSD India Plans Co-Marketing Agreement For Diabetes Drugs 126

Ezose Sciences Enters Into Co-Development Agreement With Merck 127

Vaccine & Gene Therapy Institute Enters Research Agreement With Merck 127

Redbiotec Enters Into Drug Discovery Agreement With Merck 128

Merck Enters Into Co-Development Agreement With Beijing Genomics Institute 128

Merck Enters Into Co-Development Agreement With Serum Institute of India 129

Merck Extends Co-Promotion Agreement With Roche For VICTRELIS 130

Merck Enters Into Co-Promotion Agreement With Daewoong Pharma For Vytorin 131

MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat 132

MSD In India Enters Into Co-Marketing Agreement With Sun Pharma 133

Merck Amends Distribution Agreement With Johnson & Johnson 134

Optimer Pharma Enters Into Co-Promotion Agreement With Cubist Pharma 136

TPP Global Development Enters Into Agreement With University of Aberdeen 137

ARIAD Announces Co-Promotion Agreement With Merck 138

Lycera Enters Into Research Agreement With Merck 139

Merck Enters Into An Agreement With PAREXEL International 140

Kyorin Pharma Enters into Licensing Agreement with Merck 141

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 142

Merck Enters into Licensing Agreement with BioNovion 143

Zymeworks Extends Licensing Agreement with Merck 144

Zymeworks Enters into Licensing Agreement with Merck 145

Merck Enters into Licensing Agreement with Moderna Therapeutics 146

Merck Enters into Licensing Agreement with Harvard University 147

Merck Enters into Licensing Agreement with AureoGen Biosciences 148

Merck Enters into Licensing Agreement with Cancer Research Technology 148

Adimab Enters into Licensing Agreement with Merck 150

Merck Enters into Licensing Agreement with Selvita 150

Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 151

Allergan Enters into Licensing Agreement with Merck 153

Merck Extends Licensing Agreement with Agenus 154

Arvinas Enters into Licensing Agreement with Merck 155

Merck Enters into Licensing Agreement with Medicines Patent Pool 156

XL-protein Enters into Licensing Agreement with MSD Animal Health 157

Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 158

EnWave Enters into Licensing Agreement with Merck 159

Merck Enters into Licensing Agreement with NewLink Genetics 160

Euroscreen Enters into Licensing Agreement with Merck 161

Sun Pharma Enters into Licensing Agreement with Merck 162

Kyorin Pharma Enters into Licensing Agreement with Merck 163

Bionomics Enters into Licensing Agreement with Merck for BNC375 164

Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 165

Gulf Pharma Enters into Licensing Agreement with MSD 166

NanoBio Enters Into Licensing Agreement With Merck 167

Nuevolution Enters Into Licensing Agreement With Merck 167

Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 168

Merck Expands Licensing Agreement with Ablynx 170

Polyplus-transfection Enters Into Licensing Agreement With Merck 171

AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 172

Depomed Expands Licensing Agreement With Merck For Metformin Patents 173

Bionomics Extends Licensing Agreement with Merck 174

Merck Enters Into Licensing Agreement With Lupin 175

Xencor Enters Into Licensing Agreement With Merck 176

Cerecor Enters Into Licensing Agreement With Merck For MK-0657 177

Merck Exercises Option For Licensing Agreement With Xenon Pharma For Cardiovascular Disease Targeted Compounds 178

Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 179

Merck Enters into Licensing Agreement with Ra Pharma 180

Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 181

Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 182

Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 183

Menlo Therapeutics Enters into Licensing Agreement with Merck 184

Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 185

Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 186

Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 186

Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 187

Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 189

MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 190

Merck Enters Into Licensing Agreement With Yamasa For EFdA 190

Merck Enters Into Licensing Agreement With Chimerix For CMX157 191

R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 192

Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 193

OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 194

Merck Completes Acquisition Of Inspire Pharma 293

Fujifilm Completes Acquisition Of MSD Biologics 296

Fujifilm Completes Acquisition Of Diosynth 297

Merck & Co Inc, Key Competitors 299

Merck & Co Inc, Key Employees 300

Merck & Co Inc, Subsidiaries 302

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Merck & Co Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com